NASDAQ:SLNO Soleno Therapeutics (SLNO) Stock Price, News & Analysis $49.63 -0.86 (-1.70%) (As of 10/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Soleno Therapeutics Stock (NASDAQ:SLNO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Soleno Therapeutics alerts:Sign Up Key Stats Today's Range$48.86▼$50.4950-Day Range$43.96▼$53.5552-Week Range$21.30▼$55.56Volume525,899 shsAverage Volume429,770 shsMarket Capitalization$1.66 billionP/E RatioN/ADividend YieldN/APrice Target$68.71Consensus RatingBuy Company OverviewSoleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.Read More… Revolutionary Tech Alert: How Elon Musk is Changing Lives (Ad)"Elon Musk's Neuralink just received FDA breakthrough status for a revolutionary device designed to restore vision to those who've lost it entirely. And the first human clinical trials have opened for recruitment. Click here to see it. Soleno Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks89th Percentile Overall ScoreSLNO MarketRank™: Soleno Therapeutics scored higher than 89% of companies evaluated by MarketBeat, and ranked 144th out of 1,003 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingSoleno Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSoleno Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Soleno Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Soleno Therapeutics are expected to grow in the coming year, from ($2.28) to ($2.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Soleno Therapeutics is -18.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Soleno Therapeutics is -18.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSoleno Therapeutics has a P/B Ratio of 9.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Soleno Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.00% of the float of Soleno Therapeutics has been sold short.Short Interest Ratio / Days to CoverSoleno Therapeutics has a short interest ratio ("days to cover") of 8.9.Change versus previous monthShort interest in Soleno Therapeutics has recently increased by 3.79%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSoleno Therapeutics does not currently pay a dividend.Dividend GrowthSoleno Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.55 Percentage of Shares Shorted18.00% of the float of Soleno Therapeutics has been sold short.Short Interest Ratio / Days to CoverSoleno Therapeutics has a short interest ratio ("days to cover") of 8.9.Change versus previous monthShort interest in Soleno Therapeutics has recently increased by 3.79%, indicating that investor sentiment is decreasing. News and Social Media3.2 / 5News Sentiment0.84 News SentimentSoleno Therapeutics has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Soleno Therapeutics this week, compared to 3 articles on an average week.Search Interest4 people have searched for SLNO on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Soleno Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Soleno Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $35,555,839.00 in company stock.Percentage Held by Insiders12.30% of the stock of Soleno Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.42% of the stock of Soleno Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Soleno Therapeutics' insider trading history. Receive SLNO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Soleno Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SLNO Stock News HeadlinesSoleno Therapeutics (NASDAQ:SLNO) Price Target Raised to $74.00 at Stifel NicolausOctober 1 at 1:29 PM | americanbankingnews.comSoleno Therapeutics (NASDAQ:SLNO) Shares Up 4.5%September 25, 2024 | americanbankingnews.com320 hedge funds just sold this stock320 hedge funds just sold this stock A strange force has seized control of Wall Street. Hedge funds are already moving their money… and preparing for even stranger days ahead. Over 320 hedge funds have quietly sold THIS famous stock – to prepare for a dramatic market shiftOctober 2, 2024 | Chaikin Analytics (Ad)Nantahala Capital Management Reduces Stake in America's Car-Mart IncSeptember 24, 2024 | finance.yahoo.comSoleno Therapeutics to Present at 2024 Cantor Global Healthcare ConferenceSeptember 16, 2024 | globenewswire.comSoleno Therapeutics (SLNO) Receives a Buy from Piper SandlerSeptember 11, 2024 | markets.businessinsider.comHC Wainwright & Co. Initiates Coverage of Soleno Therapeutics (SLNO) with Buy RecommendationSeptember 5, 2024 | msn.comBuy Rating on Soleno Therapeutics: Advancing PWS Treatment with DCCR and Anticipating FDA ApprovalSeptember 3, 2024 | markets.businessinsider.comSee More Headlines SLNO Stock Analysis - Frequently Asked Questions How have SLNO shares performed this year? Soleno Therapeutics' stock was trading at $40.25 at the start of the year. Since then, SLNO shares have increased by 23.3% and is now trading at $49.63. View the best growth stocks for 2024 here. How were Soleno Therapeutics' earnings last quarter? Soleno Therapeutics, Inc. (NASDAQ:SLNO) posted its earnings results on Wednesday, August, 7th. The company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.06. When did Soleno Therapeutics' stock split? Shares of Soleno Therapeutics reverse split on Friday, August 26th 2022. The 1-15 reverse split was announced on Friday, August 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Soleno Therapeutics? Shares of SLNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Soleno Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Soleno Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), OPKO Health (OPK), ADMA Biologics (ADMA), Matinas BioPharma (MTNB) and Miragen Therapeutics (MGEN). Company Calendar Last Earnings8/07/2024Today10/01/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryMedical Equipment Current SymbolNASDAQ:SLNO CUSIPN/A CIK1484565 Webwww.soleno.life Phone(650) 213-8444Fax650-213-8383Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$68.71 High Stock Price Target$93.00 Low Stock Price Target$40.00 Potential Upside/Downside+35.5%Consensus RatingBuy Rating Score (0-4)3.13 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-38,990,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-43.26% Return on Assets-36.48% Debt Debt-to-Equity RatioN/A Current Ratio29.24 Quick Ratio29.24 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.16 per share Price / Book9.60Miscellaneous Outstanding Shares33,411,000Free Float29,301,000Market Cap$1.66 billion OptionableOptionable Beta-1.46 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:SLNO) was last updated on 10/2/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored320 hedge funds just sold this stock320 hedge funds just sold this stock A strange force has seized control of Wall Street. Hedge funds are alr...Chaikin Analytics | SponsoredThey laughed when he picked Nvidia in 2016…Everyone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredFor Elon, I fear the worst is yet to come…Early last year I predicted that there would be a war on Elon Musk. This hateful rhetoric has led to two s...Porter & Company | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soleno Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soleno Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.